vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Dine Brands Global, Inc. (DIN). Click either name above to swap in a different company.
Dine Brands Global, Inc. is the larger business by last-quarter revenue ($217.6M vs $196.0M, roughly 1.1× Axsome Therapeutics, Inc.). Dine Brands Global, Inc. runs the higher net margin — -5.6% vs -14.6%, a 8.9% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 6.3%). Dine Brands Global, Inc. produced more free cash flow last quarter ($-8.6M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 2.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Dine Brands Global Inc. is a publicly traded food and beverage company based in Pasadena, California. Founded in 1958 as IHOP, it operates franchised and corporate owned full-service restaurants including three restaurant concepts, Applebee's Neighborhood Grill & Bar, International House of Pancakes (IHOP), and Fuzzy's Taco Shop.
AXSM vs DIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $217.6M |
| Net Profit | $-28.6M | $-12.2M |
| Gross Margin | — | 42.4% |
| Operating Margin | -13.8% | -7.6% |
| Net Margin | -14.6% | -5.6% |
| Revenue YoY | 65.0% | 6.3% |
| Net Profit YoY | 61.9% | -336.1% |
| EPS (diluted) | $-0.55 | $-0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $217.6M | ||
| Q3 25 | $171.0M | $216.2M | ||
| Q2 25 | $150.0M | $230.8M | ||
| Q1 25 | $121.5M | $214.8M | ||
| Q4 24 | $118.8M | $204.8M | ||
| Q3 24 | $104.8M | $195.0M | ||
| Q2 24 | $87.2M | $206.3M | ||
| Q1 24 | $75.0M | $206.2M |
| Q4 25 | $-28.6M | $-12.2M | ||
| Q3 25 | $-47.2M | $7.3M | ||
| Q2 25 | $-48.0M | $13.8M | ||
| Q1 25 | $-59.4M | $8.2M | ||
| Q4 24 | $-74.9M | $5.2M | ||
| Q3 24 | $-64.6M | $19.1M | ||
| Q2 24 | $-79.3M | $23.2M | ||
| Q1 24 | $-68.4M | $17.5M |
| Q4 25 | — | 42.4% | ||
| Q3 25 | — | 39.1% | ||
| Q2 25 | — | 40.0% | ||
| Q1 25 | — | 42.0% | ||
| Q4 24 | — | 41.7% | ||
| Q3 24 | — | 47.8% | ||
| Q2 24 | — | 48.1% | ||
| Q1 24 | — | 47.2% |
| Q4 25 | -13.8% | -7.6% | ||
| Q3 25 | -27.0% | 4.7% | ||
| Q2 25 | -24.5% | 8.2% | ||
| Q1 25 | -46.9% | 6.0% | ||
| Q4 24 | -61.1% | 3.8% | ||
| Q3 24 | -59.8% | 13.6% | ||
| Q2 24 | -89.5% | 15.1% | ||
| Q1 24 | -89.7% | 11.7% |
| Q4 25 | -14.6% | -5.6% | ||
| Q3 25 | -27.6% | 3.4% | ||
| Q2 25 | -32.0% | 6.0% | ||
| Q1 25 | -48.9% | 3.8% | ||
| Q4 24 | -63.1% | 2.5% | ||
| Q3 24 | -61.7% | 9.8% | ||
| Q2 24 | -91.0% | 11.2% | ||
| Q1 24 | -91.1% | 8.5% |
| Q4 25 | $-0.55 | $-0.79 | ||
| Q3 25 | $-0.94 | $0.48 | ||
| Q2 25 | $-0.97 | $0.89 | ||
| Q1 25 | $-1.22 | $0.53 | ||
| Q4 24 | $-1.54 | $0.35 | ||
| Q3 24 | $-1.34 | $1.24 | ||
| Q2 24 | $-1.67 | $1.50 | ||
| Q1 24 | $-1.44 | $1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $128.2M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $88.3M | $-273.9M |
| Total Assets | $689.8M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $128.2M | ||
| Q3 25 | $325.3M | $167.9M | ||
| Q2 25 | $303.0M | $194.2M | ||
| Q1 25 | $300.9M | $186.5M | ||
| Q4 24 | $315.4M | $186.7M | ||
| Q3 24 | $327.3M | $169.6M | ||
| Q2 24 | $315.7M | $153.5M | ||
| Q1 24 | $331.4M | $145.0M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $88.3M | $-273.9M | ||
| Q3 25 | $73.7M | $-231.9M | ||
| Q2 25 | $73.1M | $-212.5M | ||
| Q1 25 | $53.2M | $-215.7M | ||
| Q4 24 | $57.0M | $-216.0M | ||
| Q3 24 | $92.9M | $-216.7M | ||
| Q2 24 | $102.9M | $-231.7M | ||
| Q1 24 | $144.0M | $-244.8M |
| Q4 25 | $689.8M | $1.7B | ||
| Q3 25 | $669.3M | $1.8B | ||
| Q2 25 | $639.8M | $1.8B | ||
| Q1 25 | $596.7M | $1.8B | ||
| Q4 24 | $568.5M | $1.8B | ||
| Q3 24 | $561.5M | $1.7B | ||
| Q2 24 | $548.2M | $1.7B | ||
| Q1 24 | $545.7M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $5.7M |
| Free Cash FlowOCF − Capex | $-18.7M | $-8.6M |
| FCF MarginFCF / Revenue | -9.6% | -3.9% |
| Capex IntensityCapex / Revenue | 0.0% | 6.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $53.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $5.7M | ||
| Q3 25 | $1.0M | $30.2M | ||
| Q2 25 | $-32.4M | $37.0M | ||
| Q1 25 | $-43.4M | $16.1M | ||
| Q4 24 | $-26.2M | $30.5M | ||
| Q3 24 | $-18.6M | $25.5M | ||
| Q2 24 | $-30.1M | $21.6M | ||
| Q1 24 | $-53.5M | $30.6M |
| Q4 25 | $-18.7M | $-8.6M | ||
| Q3 25 | $988.0K | $18.1M | ||
| Q2 25 | $-32.4M | $31.0M | ||
| Q1 25 | $-43.7M | $12.8M | ||
| Q4 24 | $-26.2M | $26.7M | ||
| Q3 24 | $-18.7M | $22.0M | ||
| Q2 24 | $-30.2M | $18.2M | ||
| Q1 24 | $-53.6M | $27.2M |
| Q4 25 | -9.6% | -3.9% | ||
| Q3 25 | 0.6% | 8.4% | ||
| Q2 25 | -21.6% | 13.4% | ||
| Q1 25 | -36.0% | 6.0% | ||
| Q4 24 | -22.1% | 13.0% | ||
| Q3 24 | -17.9% | 11.3% | ||
| Q2 24 | -34.6% | 8.8% | ||
| Q1 24 | -71.4% | 13.2% |
| Q4 25 | 0.0% | 6.6% | ||
| Q3 25 | 0.0% | 5.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.3% | 1.5% | ||
| Q4 24 | 0.0% | 1.9% | ||
| Q3 24 | 0.1% | 1.8% | ||
| Q2 24 | 0.1% | 1.7% | ||
| Q1 24 | 0.1% | 1.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.12× | ||
| Q2 25 | — | 2.68× | ||
| Q1 25 | — | 1.97× | ||
| Q4 24 | — | 5.88× | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | — | 1.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
DIN
| Franchisor | $163.2M | 75% |
| Food And Beverage | $27.3M | 13% |
| Proprietary Product Sales And Other | $17.0M | 8% |
| Other | $8.1M | 4% |
| Franchise And Development Fees | $2.0M | 1% |
